Squarepoint Ops LLC Takes $675,000 Position in Cellebrite DI Ltd. $CLBT

Squarepoint Ops LLC purchased a new position in Cellebrite DI Ltd. (NASDAQ:CLBT) during the second quarter, HoldingsChannel reports. The firm purchased 42,199 shares of the company’s stock, valued at approximately $675,000.

A number of other hedge funds also recently bought and sold shares of CLBT. Voss Capital LP lifted its holdings in Cellebrite DI by 34.0% in the second quarter. Voss Capital LP now owns 5,150,000 shares of the company’s stock valued at $82,400,000 after acquiring an additional 1,306,398 shares during the period. Phoenix Financial Ltd. lifted its stake in shares of Cellebrite DI by 153.5% in the 2nd quarter. Phoenix Financial Ltd. now owns 2,014,617 shares of the company’s stock worth $32,232,000 after purchasing an additional 1,219,958 shares during the period. Handelsbanken Fonder AB lifted its stake in shares of Cellebrite DI by 61.3% in the 2nd quarter. Handelsbanken Fonder AB now owns 2,450,000 shares of the company’s stock worth $39,200,000 after purchasing an additional 931,300 shares during the period. Thematics Asset Management purchased a new position in shares of Cellebrite DI in the second quarter worth approximately $13,919,000. Finally, Royal Bank of Canada grew its position in Cellebrite DI by 11,705.0% during the first quarter. Royal Bank of Canada now owns 824,226 shares of the company’s stock valued at $16,015,000 after buying an additional 817,244 shares during the period. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Stock Performance

Shares of CLBT stock opened at $18.88 on Wednesday. The stock has a fifty day simple moving average of $17.71 and a two-hundred day simple moving average of $16.68. The firm has a market capitalization of $4.52 billion, a PE ratio of 60.90, a PEG ratio of 3.29 and a beta of 1.29. Cellebrite DI Ltd. has a 52-week low of $13.10 and a 52-week high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings data on Wednesday, November 12th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.13 by ($0.05). The business had revenue of $126.03 million during the quarter, compared to analysts’ expectations of $122.98 million. Cellebrite DI had a net margin of 16.74% and a return on equity of 20.81%. Cellebrite DI’s revenue was up 17.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.14 earnings per share. On average, sell-side analysts forecast that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Lake Street Capital increased their price target on shares of Cellebrite DI from $22.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Needham & Company LLC raised their target price on Cellebrite DI from $22.00 to $24.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Bank of America boosted their price target on Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, November 13th. JPMorgan Chase & Co. raised their price objective on Cellebrite DI from $23.00 to $24.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. Finally, Wall Street Zen downgraded Cellebrite DI from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Cellebrite DI presently has an average rating of “Moderate Buy” and an average price target of $24.00.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.